Pharmaceuticals News 23 October 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price

26 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Investment News · Pharmaceuticals · Stock Market

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and

25 November 2025

Biotech · Investing · Pharmaceuticals · Stock Market

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Snapshot: Where RXRX Stands Going Into the New Week Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at

24 November 2025

Artificial Intelligence · Institutional Investors · Investing · Pharmaceuticals · Stock Market

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining

23 November 2025

Company News · Financial Analysis · Investment Strategies · Pharmaceuticals · Stock Market

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity

20 November 2025

Biotechnology · Business News · Healthcare Industry · Investment · Pharmaceuticals

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer Inc. (NYSE: PFE) is back in the headlines today with a flurry of developments that span new product launches, obesity-drug M&A, fresh vaccine data and ongoing debate about whether its battered stock is finally a buy. As of this

17 November 2025

Business Deals · Pharmaceuticals · Stock Market

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on

17 November 2025

Biotech Industry · Mergers & Acquisitions · Pharmaceuticals

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence

5 November 2025

Business News · Healthcare Industry · Investing · Pharmaceuticals · Stock Market

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

FDA Setback: Complete Response Letter Halts Lead Drug Ambitions Biohaven’s recent troubles center on VYGLXIA (troriluzole) – its lead drug candidate for spinocerebellar ataxia (SCA), a degenerative brain disorder that currently has no approved treatment reuters.com. On November 4, 2025,

5 November 2025

Biotech · Investing · Pharmaceuticals · Stocks

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 markets.financialcontent.com) after a prior drop (–23% on Oct 8 benzinga.com). Recent

24 October 2025

Biotechnology · Clinical Trials · Pharmaceuticals · Stock Market

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on record directorstalkinterviews.com. By comparison,

23 October 2025

Investment · Market Analysis · Pharmaceuticals · Stocks · Wall Street

Pharmaceuticals News 23 October 2025 - 26 November 2025